Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in pretreated HER2 exon 20-mutant advanced NSCLC
NL-OMON42560Phase 2Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of afatinib, sponsored by European Thoracic Oncology Platform. Started Aug 2015; status: active, not recruiting.
02
Drugs
afatinib
Beyond the preview
Go deeper on NL-OMON42560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42560.